{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:30:57Z","timestamp":1794241857482,"version":"4.9.0"},"reference-count":77,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Quantitative fibrinogen disorders, including afibrinogenemia and hypofibrinogenemia, are defined by the complete absence or reduction of fibrinogen, respectively. The diagnosis is based on the measurement of fibrinogen activity and antigen levels, which define the severity of this monogenic disorder. Afibrinogenemia is the result of homozygosity or combined heterozygosity for the causative mutations, whereas monoallelic mutations lead to hypofibrinogenemia. The bleeding phenotype varies in accordance with fibrinogen levels, ranging generally from frequent and often life-threatening bleeding in afibrinogenemia to the absence of symptoms, or mild bleeding symptoms in mild hypofibrinogenemia. The main treatment for quantitative fibrinogen disorders is fibrinogen supplementation. Despite low fibrinogen levels, a tendency for thrombosis is a characteristic of these disorders and may be exacerbated by fibrinogen supplementation. The management of surgery and pregnancy presents significant challenges regarding the amount of fibrinogen replacement and the need for thromboprophylaxis. The objective of this article is to present 4 clinical scenarios that illustrate common clinical challenges and to propose strategies for managing bleeding, thrombosis, surgery, and pregnancy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025712","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T22:01:57Z","timestamp":1734645717000},"page":"801-810","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["How I treat quantitative fibrinogen disorders"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-933X","authenticated-orcid":false,"given":"Alessandro","family":"Casini","sequence":"first","affiliation":[{"name":"Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland; and Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2025032119415316000_bib1","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"Palla","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2025032119415316000_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1365-2516.2008.01831.x","article-title":"Rare inherited disorders of fibrinogen","volume":"14","author":"Acharya","year":"2008","journal-title":"Haemophilia"},{"issue":"9","key":"2025032119415316000_bib3","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/jth.14216","article-title":"Diagnosis and classification\u00a0of congenital fibrinogen disorders: communication from the SSC of the ISTH","volume":"16","author":"Casini","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2025032119415316000_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.14201","article-title":"International council for standardisation in haematology recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders","volume":"46","author":"Mackie","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"2025032119415316000_bib5","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood.2020010116","article-title":"How I treat dysfibrinogenemia","volume":"138","author":"Casini","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025032119415316000_bib76","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3390\/ijms18122717","article-title":"Fibrinogen gamma chain mutations provoke fibrinogen and apolipoprotein B plasma deficiency and liver storage","volume":"18","author":"Callea","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025032119415316000_bib6","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.blre.2020.100793","article-title":"Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management","volume":"48","author":"Casini","year":"2021","journal-title":"Blood Rev"},{"issue":"3","key":"2025032119415316000_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.mbc.0000164430.98169.c6","article-title":"gammaAla82Gly represents a common fibrinogen gamma-chain variant in Caucasians","volume":"16","author":"Ivaskevicius","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"2025032119415316000_bib8","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.3390\/ijms18122711","article-title":"Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of A\u03b1, B\u03b2,\u00a0and \u03b3chains","volume":"18","author":"Paraboschi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025032119415316000_bib9","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/hae.14529","article-title":"Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States","volume":"28","author":"Miller","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"2025032119415316000_bib10","first-page":"154","article-title":"The molecular basis of inherited afibrinogenaemia","volume":"86","author":"Neerman-Arbez","year":"2001","journal-title":"Thromb Haemost"},{"issue":"10","key":"2025032119415316000_bib11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/j.1538-7836.2006.02094.x","article-title":"The molecular basis of quantitative fibrinogen disorders","volume":"4","author":"Asselta","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2025032119415316000_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1055\/s-0041-1742170","article-title":"Mutations accounting for congenital fibrinogen disorders: an update","volume":"48","author":"Richard","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2025032119415316000_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/hae.14773","article-title":"Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies","volume":"29","author":"Mohsenian","year":"2023","journal-title":"Haemophilia"},{"issue":"4","key":"2025032119415316000_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2025032119415316000_bib15","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/bloodadvances.2023012186","article-title":"Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the prospective rare bleeding disorders database","volume":"8","author":"Mohsenian","year":"2024","journal-title":"Blood Adv"},{"issue":"22","key":"2025032119415316000_bib16","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood.2020009472","article-title":"Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia","volume":"137","author":"Casini","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025032119415316000_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/hae.14738","article-title":"High incidence of intracranial haemorrhage in Egyptian children with congenital afibrinogenaemia","volume":"29","author":"Abdelwahab","year":"2023","journal-title":"Haemophilia"},{"key":"2025032119415316000_bib18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.thromres.2019.07.014","article-title":"The use of prophylaxis in the treatment of rare bleeding disorders","volume":"196","author":"Shapiro","year":"2020","journal-title":"Thromb Res"},{"issue":"8","key":"2025032119415316000_bib19","doi-asserted-by":"crossref","first-page":"e0290571","DOI":"10.1371\/journal.pone.0290571","article-title":"Differences in coagulation-relevant parameters: comparing cryoprecipitate and a human fibrinogen concentrate","volume":"18","author":"Stanford","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"2025032119415316000_bib20","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1097\/MPH.0000000000001812","article-title":"Blood, sweat, and fears: a novel mutation associated with anaphylaxis and nonresponse in a patient with afibrinogenemia","volume":"43","author":"Hsieh","year":"2021","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"4","key":"2025032119415316000_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/vox.12424","article-title":"Post-authorization safety study of Clottafact\u00ae, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study","volume":"111","author":"Negrier","year":"2016","journal-title":"Vox Sang"},{"issue":"4","key":"2025032119415316000_bib22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1160\/TH14-06-0514","article-title":"Safety\u00a0of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data","volume":"113","author":"Solomon","year":"2015","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"2025032119415316000_bib23","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(09)70159-8","article-title":"Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?","volume":"124","author":"Bevan","year":"2009","journal-title":"Thromb Res"},{"key":"2025032119415316000_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0002-9343(61)90057-2","article-title":"Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia","volume":"30","author":"De Vries","year":"1961","journal-title":"Am J Med"},{"issue":"2","key":"2025032119415316000_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/trf.14421","article-title":"Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial","volume":"58","author":"Lissitchkov","year":"2018","journal-title":"Transfusion"},{"issue":"6","key":"2025032119415316000_bib26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-0040-1710015","article-title":"Pharmacology, efficacy and safety of a triple-secured fibrinogen concentrate in children less than or equal to 12 years with afibrinogenaemia","volume":"120","author":"Djambas Khayat","year":"2020","journal-title":"Thromb Haemost"},{"issue":"4","key":"2025032119415316000_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/jth.14392","article-title":"Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency","volume":"17","author":"Djambas Khayat","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2025032119415316000_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/hae.14230","article-title":"Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency","volume":"27","author":"Djambas Khayat","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2025032119415316000_bib29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jth.14727","article-title":"Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients","volume":"18","author":"Lissitchkov","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2025032119415316000_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jth.13923","article-title":"Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency","volume":"16","author":"Ross","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2025032119415316000_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2516.2004.00944.x","article-title":"The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"10","author":"Bolton-Maggs","year":"2004","journal-title":"Haemophilia"},{"issue":"6","key":"2025032119415316000_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13941","article-title":"Management of rare inherited bleeding disorders: proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders","volume":"110","author":"Trossaert","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025032119415316000_bib33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"2025032119415316000_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/hae.13061","article-title":"Management of congenital quantitative fibrinogen disorders: a Delphi consensus","volume":"22","author":"Casini","year":"2016","journal-title":"Haemophilia"},{"issue":"6","key":"2025032119415316000_bib35","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1111\/hae.13620","article-title":"Thromboelastography and thrombin generation assay in inherited afibrinogenemia","volume":"24","author":"Young","year":"2018","journal-title":"Haemophilia"},{"issue":"2","key":"2025032119415316000_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bcp.14147","article-title":"Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: observed age- and body weight-related differences and consequences for dose adjustment in children","volume":"86","author":"Bellon","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2025032119415316000_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13876","article-title":"Fibrinogen concentrates in hereditary fibrinogen disorders: past, present and future","volume":"26","author":"Casini","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2025032119415316000_bib38","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1537-2995.2010.02612.x","article-title":"Is primary prophylaxis required in afibrinogenemia?","volume":"50","author":"Polack","year":"2010","journal-title":"Transfusion"},{"issue":"7","key":"2025032119415316000_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1538-7836.2006.02014.x","article-title":"Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia","volume":"4","author":"Peyvandi","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2025032119415316000_bib40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/rth2.12433","article-title":"Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: observational study of efficacy and safety for prophylaxis and treatment","volume":"4","author":"Lasky","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025032119415316000_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2516.2007.01564.x","article-title":"Central venous catheter-related thrombosis after replacement therapy for intracranial bleeding in a patient with afibrinogenaemia","volume":"14","author":"Matsumoto","year":"2008","journal-title":"Haemophilia"},{"issue":"2","key":"2025032119415316000_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000452864","article-title":"Thrombosis in inherited fibrinogen disorders","volume":"44","author":"Korte","year":"2017","journal-title":"Transfus Med Hemother"},{"issue":"9","key":"2025032119415316000_bib43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/j.1538-7836.2011.04424.x","article-title":"Fibrinogen replacement\u00a0therapy for congenital fibrinogen deficiency","volume":"9","author":"Bornikova","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2025032119415316000_bib44","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.jtha.2023.04.035","article-title":"Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study","volume":"21","author":"Hugon-Rodin","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2025032119415316000_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/hae.12507","article-title":"Thrombosis of abdominal aorta in congenital afibrinogenemia: case report and review of literature","volume":"21","author":"Sartori","year":"2015","journal-title":"Haemophilia"},{"issue":"3","key":"2025032119415316000_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0049-3848(01)00247-X","article-title":"Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in\u00a0vivo circulating thrombin","volume":"102","author":"Dupuy","year":"2001","journal-title":"Thromb Res"},{"issue":"5","key":"2025032119415316000_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0036-1581103","article-title":"Severe thrombotic complications in congenital afibrinogenemia: a pathophysiological and management dilemma","volume":"42","author":"Santoro","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2025032119415316000_bib48","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ijms22020655","article-title":"Venous thrombosis and thrombocyte activity in Zebrafish models of quantitative and qualitative fibrinogen disorders","volume":"22","author":"Fish","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025032119415316000_bib49","first-page":"105","article-title":"Update on antithrombin I (fibrin)","volume":"98","author":"Mosesson","year":"2007","journal-title":"Thromb Haemost"},{"issue":"5","key":"2025032119415316000_bib50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF00252836","article-title":"Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution","volume":"72","author":"Korte","year":"1994","journal-title":"Clin Investig"},{"issue":"4","key":"2025032119415316000_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.thromres.2010.12.011","article-title":"Simultaneous thrombin and plasmin generation capacities in normal and\u00a0abnormal states of coagulation and fibrinolysis in children and adults","volume":"127","author":"Simpson","year":"2011","journal-title":"Thromb Res"},{"key":"2025032119415316000_bib52","doi-asserted-by":"crossref","first-page":"10760296241254106","DOI":"10.1177\/10760296241254106","article-title":"Long-term safety analysis of a fibrinogen concentrate (RiaSTAP\u00ae\/Haemocomplettan\u00ae\u00a0P)","volume":"30","author":"Rahe-Meyer","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"2025032119415316000_bib53","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1055\/a-1745-0420","article-title":"Impact of fibrinogen infusion on thrombin generation and fibrin clot structure in patients with inherited afibrinogenemia","volume":"122","author":"Khayat","year":"2022","journal-title":"Thromb Haemost"},{"issue":"4","key":"2025032119415316000_bib54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1160\/TH16-02-0082","article-title":"Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review","volume":"116","author":"Nagler","year":"2016","journal-title":"Thromb Haemost"},{"issue":"5","key":"2025032119415316000_bib55","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1111\/hae.12734","article-title":"Venous thrombosis in afibrinogenemia: a successful use of rivaroxaban","volume":"21","author":"Margaglione","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"2025032119415316000_bib56","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1017\/cjn.2018.57","article-title":"Ischemic strokes in a man with congenital afibrinogenemia","volume":"45","author":"Nathoo","year":"2018","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"2025032119415316000_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcla.21722","article-title":"Comparison of prothrombin time derived from CoaguChek XS and laboratory test according to fibrinogen level","volume":"29","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"6","key":"2025032119415316000_bib58","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance","volume":"7","author":"Schutgens","year":"2023","journal-title":"Hemasphere"},{"issue":"19","key":"2025032119415316000_bib59","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2025032119415316000_bib60","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/hae.14579","article-title":"Clinical, biological, and genetic features in an afibrinogenemia patient series in Algeria","volume":"28","author":"Hadjali-Saichi","year":"2022","journal-title":"Haemophilia"},{"issue":"4","key":"2025032119415316000_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jth.15652","article-title":"Treatment of patients with rare bleeding disorders in the Netherlands: real-life data from the RBiN study","volume":"20","author":"Maas","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2025032119415316000_bib62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ajh.20802","article-title":"Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions","volume":"82","author":"Aygoren-Pursun","year":"2007","journal-title":"Am J Hematol"},{"key":"2025032119415316000_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.01.024","article-title":"Perioperative management of a severe congenital hypofibrinogenemia with thrombotic phenotype","volume":"188","author":"Simurda","year":"2020","journal-title":"Thromb Res"},{"issue":"11","key":"2025032119415316000_bib77","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/jth.14598","article-title":"Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural\/surgical bleed risk and patient-specific thromboembolic risk","volume":"17","author":"Spyropoulos","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2025032119415316000_bib64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.thromres.2013.08.023","article-title":"The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading","volume":"132","author":"Snir","year":"2013","journal-title":"Thromb Res"},{"issue":"5","key":"2025032119415316000_bib65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/1389450054546006","article-title":"Maternal fibrinogen\u00a0is\u00a0necessary for embryonic development","volume":"6","author":"Iwaki","year":"2005","journal-title":"Curr Drug Targets"},{"issue":"2","key":"2025032119415316000_bib66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/rth2.12300","article-title":"Pregnancy outcome in afibrinogenemia: are we giving enough fibrinogen concentrate? A case series","volume":"4","author":"Saes","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2025032119415316000_bib67","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1111\/hae.13415","article-title":"Successful delivery in an patient with afibrinogenemia after three abortions: a case report and review of the literature","volume":"24","author":"Karimi","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"2025032119415316000_bib68","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1111\/hae.13054","article-title":"Three successful deliveries involving a woman with congenital afibrinogenaemia - conventional fibrinogen concentrate infusion vs. 'as required' fibrinogen concentrate infusion based on changes in fibrinogen clearance","volume":"22","author":"Oda","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"2025032119415316000_bib69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2516.2010.02363.x","article-title":"Congenital afibrinogenaemia in pregnancy","volume":"17","author":"Mensah","year":"2011","journal-title":"Haemophilia"},{"issue":"5","key":"2025032119415316000_bib70","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1447-0756.2008.00859.x","article-title":"Interstitial pregnancy in a woman with congenital afibrinogenemia","volume":"34","author":"Matsushita","year":"2008","journal-title":"J\u00a0Obstet Gynaecol Res"},{"issue":"3","key":"2025032119415316000_bib71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.20110","article-title":"Pregnancy-related thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies","volume":"76","author":"Roque","year":"2004","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032119415316000_bib72","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1111\/hae.12584","article-title":"Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis","volume":"21","author":"Lebreton","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"2025032119415316000_bib73","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.jtha.2024.01.008","article-title":"Management of pregnancy and delivery in congenital fibrinogen disorders: communication from the ISTH SSC Subcommittee on factor XIII and fibrinogen","volume":"22","author":"Casini","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2025032119415316000_bib74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0042-1758117","article-title":"Planning pregnancy and birth in women with inherited bleeding disorders","volume":"49","author":"Malinowski","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2025032119415316000_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.2830490427","article-title":"Congenital afibrinogenemia: successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive","volume":"49","author":"Castaman","year":"1995","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/8\/801\/2355735\/blood_bld-2024-025712-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/8\/801\/2355735\/blood_bld-2024-025712-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:30:59Z","timestamp":1742589059000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/8\/801\/534789\/How-I-treat-quantitative-fibrinogen-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025712","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}